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Abstract: Lung diseases such as fibrosis, asthma, cystic fibrosis, infection and cancer are life-threatening 
conditions that slowly deteriorate quality of life and for which our diagnostic power is high, but our 
knowledge on etiology and/or effective treatment options still contains important gaps. In the context 
of day-to-day practice, clinical and preclinical studies, clinicians and basic researchers team up and 
continuously strive to increase insights into lung disease progression, diagnostic and treatment options. 
To unravel disease processes and to test novel therapeutic approaches, investigators typically rely on 
end-stage procedures such as serum analysis, cyto-/chemokine profiles and selective tissue histology 
from animal models. These techniques are useful but provide only a snapshot of disease processes 
that are essentially dynamic in time and space. Technology allowing evaluation of live animals 
repeatedly is indispensable to gain a better insight into the dynamics of lung disease progression and 
treatment effects. Computed tomography (CT) is a clinical diagnostic imaging technique that can 
have enormous benefits in a research context too. Yet, the implementation of imaging techniques in 
laboratories lags behind. In this review we want to showcase the integrated approaches and novel 
developments in imaging, lung functional testing and pathological techniques that are used to assess, 
diagnose, quantify and treat lung disease and that may be employed in research on patients and 
animals. Imaging approaches result in often novel anatomical and functional biomarkers, resulting 
in many advantages, such as better insight in disease progression and a reduction in the numbers 
of animals necessary. We here showcase integrated assessment of lung disease with imaging and 
histopathological technologies, applied to the example of lung fibrosis. Better integration of clinical 
and preclinical imaging technologies with pathology will ultimately result in improved clinical 
translation of (therapy) study results.
Keywords: imaging-histopathology correlation; gCT; MRI; optical imaging; virtual biopsy; clinical; 
experimental; lung fibrosis
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1. Current Challenges in Lung Disease Management
Computed tomography (CT) is an integral part of the diagnostic and therapeutic workup of many 
lung diseases. This imaging technique produces images that can be used for diagnosis, to determine 
therapeutic options and to follow-up on the outcome of the patient during treatment. Unfortunately, 
treatment is often limited to relieving symptoms or stopping progression since curative treatment is not 
always possible or available. Lung diseases are among the most important causes of illness and death 
in the world nowadays. Chronic obstructive pulmonary disease, lung cancer, fibrosis, emphysema and 
asthma are examples of such devastating and life-threatening conditions. Researchers are therefore 
continuously investigating novel strategies to prevent and cure lung diseases. Even when sometimes 
the cause is obvious (e.g., cigarette smoking, allergens, environmental pollutants), many aspects of 
what exactly causes the disease remain to be understood in order to find targets for new, effective 
treatment options.
Whereas imaging examinations are routine clinical practice, preclinical investigators typically 
rely on the analysis of lung tissue samples from indispensable animal models (mainly rodents) to 
unravel disease processes in the lung. Although these and other end-stage techniques provide plenty 
of opportunities for detailed molecular and microscopic evaluation of pathology, they are limited to 
one measurement per animal, providing only a snapshot of processes that are essentially dynamic. 
The identification of important factors for disease onset and progression and putative therapies are 
often investigated in survival studies, comparing delays in death between experimental and control 
groups. Animals are left to succumb to disease, while every opportunity to investigate what happened 
during disease progression within the lungs— pathology and host response thereto— is lost.
At the same time, we are confronted with important challenges related to the translation of mouse 
study results to patients. Regarding the treatment of, for example, lung fibrosis, most if not all of 
the putative therapies that were successfully tested in rodent models afterwards failed in clinical 
studies [1,2]. Failure to translate "proof-of-principle" approaches from in vitro and in vivo models 
has discouraged scientists, clinicians and pharmaceutical companies in the management of fibrotic 
disorders such as idiopathic lung fibrosis or fibrosis in the context of systemic sclerosis or environmental 
exposure [1,3]. For these devastating conditions, effective anti-fibrotic treatment is still lacking [4].
Specific technological advances and optimization of existing approaches should now answer to 
the so-called translational challenges in the field. We put forward that combined quantitative in vivo 
assessment of the functional and structural changes throughout disease progression in each individual 
animal should increasingly be used to overcome challenges in translation of laboratory research to 
clinical applications. Improved quantitative and dynamic imaging of animal models should increase 
knowledge of the kinetics of pathophysiological processes at play. More accurate description of the 
effects of therapeutic interventions will increase the probability of successful translation to clinical 
practice, ultimately reducing unnecessary financial expenses or animal use and improving target 
selection for clinical trials.
Imaging of small animal models of disease provides unique opportunities for model evaluation 
and for obtaining mechanistic insights into pathological processes. Micro-computed tomography 
(pCT) in particular, and also magnetic resonance imaging (MRI), provide specific insights into the 
onset and progression of fibrotic lung disease and response to treatment [4- 9]. These approaches 
overcome several limitations that were previously associated with animal models of fibrosis: most 
scoring methods relied on single end-point measurements of what is essentially a dynamic disease 
process in an individual animal.
Yet, despite the validation and the obvious advantages of quantitative imaging outcomes, 
the semi-quantitative assessment through a scoring system by histological analysis of isolated organs 
post mortem remains the current and often only gold standard. Whereas ex vivo analyses of 
tissue samples can provide the most detailed cellular and molecular analysis of the disease, they are 
intrinsically unable to follow the kinetics of disease and host response processes which are, by definition, 
dynamic in space and time. Ex vivo analyses require multiple animals to be sacrificed at several time
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points during the study, carrying the ethical burden of overconsumption of animals to overcome the 
statistical issues inherent to high inter-animal variation that would otherwise reduce the power of 
experiments. Moreover, one- or two-dimensional sampling alone is too limited for processes that are 
not evenly distributed throughout an entire organ, such as the pulmonary lobes in lung fibrosis [6 ]. 
In addition, the sensitivity, specificity and available readouts associated with non-invasive pulmonary 
function measurements indicate the considerable limitations of ex vivo approaches [10- 12]. They are 
valuable options and provide a lot of very relevant and meaningful information, but these should 
be regarded as end-stage measurements. Moreover, they are limited in providing information on 
the spatial distribution of pathology, obscuring possible heterogeneity in disease manifestation and 
distribution throughout the lungs.
New technologies are indispensable to provide, in a non-invasive manner, multiple relevant 
morphological and functional biomarkers to longitudinally describe how the lungs change during 
disease and therapy in animal models of lung disease.
Because we rely entirely on investigations using experimental animal models in order to close the 
gaps in our knowledge regarding lung diseases and treatment, the accurate evaluation of what happens 
in individual animal models of disease and the correlation between different, often complementary 
readouts are of crucial importance for the interpretation and interpolation towards the clinical context. 
Because the current gold standard methodology that is used in lung research labs is not able to capture 
the dynamic nature of disease processes and host responses, we believe that the lung research field 
would benefit from a technological leap forward from the current methodological paradigm.
Our aim is to here provide an overview of what the current available diagnostic imaging 
technologies have to offer towards gaining new insights that would bridge the current translational 
gap and to push forward our knowledge regarding lung disease etiology and progression, with the 
ultimate aim of identifying new therapeutic targets and strategies. Our specific aim for this review is 
to improve the current standard workflow by demonstrating the added value of novel technologies 
that can contribute to better mechanistic knowledge of lung disease processes in the context of lung 
fibrosis such as parenchymal fibrosis and airway remodeling, its relation with inflammation and 
potential treatment strategies, with the ambition of improving lung disease management in lung 
fibrosis and beyond.
2. Imaging and Pathology for Diagnosis of Lung Fibrosis in Clinical Practice
2.1. Diagnostic Imaging ofILD in Clinical Practice
High resolution CT (HRCT) is the major component in the differential diagnosis and follow-up 
of interstitial lung diseases (ILD). Other imaging modalities such as MRI are currently not routinely 
used in clinical examinations. ILD encompasses a group of more than 200 lung diseases of which 
idiopathic pulmonary fibrosis (IPF) is the most frequent. A multidisciplinary expert team consisting 
amongst others of pneumologists, radiologists and pathologists is mandatory for the diagnosis of 
IPF of which diagnosis is based on combining CT findings [13] with clinical history, pulmonary 
function testing, serological testing, bronchoalveolar lavage (BAL) analysis and, when necessary, 
histopathology. The use of HRCT has reduced the use of lung biopsy to confirm diagnosis of IPF. 
Therefore, lung biopsies are currently only recommended for those cases where major discordancy is 
seen between CT and clinical findings [13].
2.2. HRCT-Derived Biomarkers ofUIP
The HRCT correlate of IPF is usual interstitial pneumonia (UIP). HRCT features seen in UIP typically 
include irregular reticulation, honeycombing, traction bronchiectasis and traction bronchiolectasis with 
the potential presence of ground-glass opacification, fine reticulation and pleural thickening [14,15] 
(Figure 1a). Honeycombing refers to clusters of cystic airspaces of consistent diameter and presents 
as multiple layers of subpleural cysts on top of each other. Subpleural and basal presence of traction
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bronchiectasis/bronchiolectasis is a key feature of pulmonary fibrosis in the setting of IPF, especially 
when associated with the presence of honeycomb cysts [16,17]. Traction bronchiectasis/ bronchiolectasis 
and honeycombing are however not always present, making diagnosis of IPF more difficult. In addition, 
UIP is also seen in other lung diseases like hypersensitivity pneumonitis, drug-induced lung disease 
and some collagen vascular diseases and therefore require a multidisciplinary discussion. Ground-glass 
opacification, which presents as a region of slightly increased lung density in which the edges of the 
pulmonary vessels and airways stay visible [14], is not a typical feature of IPF but can be seen in 
early disease.
Figure 1. HRCT and Histopathological features for diagnosis of human UIP pattern, and overview of 
the potential use of CT and pCT for understanding the clinical pathology of end-stage IPF. Panel (a), 
HRCT: (A) Typical UIP in the setting of IPF. The presence of a peripheral, subpleural predominantly 
basal irregular reticular pattern, basal honeycombing and peripheral haction bronchiectasis ma kes IPF 
very likely; (B) Probable UIP in the; setting of IPF. Peripheral and subpleural irregular reticular pattern 
with distal traction laronchiectasis but without honeycombing makes IPF very -ikily in case also clinical
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findings suggest this diagnosis; (C) Nonspecific interstitial pneumonia (NSIP). The dominant presence of 
ground-glass opacity together with a fine regular reticular pattern and proximal traction bronchiectasis 
makes IPF less likely; (D) Chronic fibrotic hypersensitivity pneumonitis. Irregular lines and reticular 
pattern are present throughout both lungs without peripheral dominance. In addition, lung density is 
inhomogeneous. IPF is unlikely and clinical arguments for an alternative diagnosis should be looked for. 
Panel (b): Histopathology of human lung (HE-staining). (A) Presence of honeycombing (inset, enlarged 
from yellow box, black stars) by formation of cystic airspaces of varying sizes filled with mucus and 
lined by bronchiolar epithelium (A scale bar = 2 mm, scale bar in inset = 500 pm); (B) Fibroblast foci 
showing interstitial ongoing fibrosis without inflammatory infiltrates are indicated by black arrows 
(scale bar = 100 pm). Panel (c): In vivo chest HRCT scan 6 months prior to transplantation with a 
resolution of around 1 mm (A); Ex vivo CT of the transplanted lung highlighting an increased spatial 
resolution due to the absence of breathing artefacts (B); Whole lung ex vivo pCT showing sagittal view 
with a resolution up to 150 pm (C); Core pCT with a resolution of 10 pm provides insight into different 
areas within the lower lobe showing severe fibrosis (red cylinder) and a near-normal area (orange 
cylinder) demonstrating the need for rigorous characterization of separate regions within the same 
lung specimen (D,E).
2.3. Histopathological Features o f the UIP Pattern
The pathological correlate of IPF is UIP. However, no pathognomonic histological criteria exist for 
the diagnosis of UIP, and the diagnosis is based on detection of several major histological criteria [13] 
(Figure 1b). Dense fibrosis with hyalinized collagen is typically found destructing the alveolar 
architecture, and presents with patchy involvement, most pronounced in the subpleural and paraseptal 
area. Normally preserved lung parenchyma may persist in the centrilobular regions. In the fibrotic 
zones, an accompanying mild inflammatory infiltrate may be present. Honeycomb changes are another 
major finding, characterized by formation of cystic airspaces of varying size filled with mucus, and lined 
by bronchiolar epithelium [13]. Fibroblast foci, indicating active fibrogenesis, are often present and 
characterized by proliferation of myofibroblasts with a pale matrix, directly adjacent to advanced fibrotic 
regions. In addition, many other histological findings may be present (e.g., peribronchiolar metaplasia, 
emphysema). Four levels of certainty for the histological diagnosis of UIP have been proposed. A 
definite diagnosis of UIP can only be made when there is presence of marked fibrosis with architectural 
destruction, patchy involvement and fibroblast foci [18]. In contrast, presence of granulomas, marked 
inflammation outside fibrotic regions, hyaline membranes, preferential airway-centered involvement 
and organizing pneumonia, are not consistent with the diagnosis of a UIP pattern, and point towards 
an alternative diagnosis.
2.4. BAL Analysis in Parallel with HRCT
In the evaluation of patients with suspected ILD, BAL held considerable promise to diagnose and 
identify various subtypes of ILD. BAL is used to assess the micro-environment of the airways and 
is able to gain further insight in the molecular processes present within the lung, but is a relatively 
invasive procedure. Nowadays, the advancements in HRCT and non-invasive detection of specific 
scanning patterns allow differentiation of certain forms of ILD and reduce the clinical utility of BAL [19]. 
However, BAL cellular characterization is still a useful tool in conjunction with radiological examination 
to confirm and fine-tune the clinical diagnosis, which results in improved patient management [20] 
and is also considered an important research tool. For example, analysis of the bacterial burden in BAL 
fluid show this to be a risk factor for disease progression and mortality, independent of the results 
assessed by longitudinal HRCT [21].
2.5. The Role of HRCT in Clinical Lung Fibrosis Research
Accurate assessment of disease severity and progression over time is crucial in estimating clinical 
prognosis and efficacy of potential therapeutics. Currently, the standard primary end-point in clinical
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trials towards IPF is a change in forced vital capacity (FVC) to monitor disease progression. Obtaining 
a sensitive and objective biomarker that is able to accurately assess disease progression is lacking. 
Despite the essential role of HRCT in the evaluation of patients with pulmonary fibrosis, it is only used 
as entry criteria into clinical trials due to inter-observer variation and appears to be insufficient for 
precise longitudinal evaluation [22] . Due to this inter-observer variability, the prognostic information 
by visual assessment of scanning patterns appears inaccurate. Advances in HRCT image analysis such 
as observer-independent and deep-learning approaches hold a strong potential towards improving 
this in the future [23,24].
Given the aforementioned incremental importance of imaging in diagnosis and management of 
pulmonary fibrosis, a lot of research has focused on more extensive in vivo and ex vivo use of imaging. 
Initially, this was mostly centered on visual scoring by a radiologist, where the extent of fibrosis 
or visible honeycombing was associated with mortality [25]. More recently, the change in traction 
bronchiectasis was also demonstrated to be of prognostic importance, and proved to be more predictive 
of mortality than FVC [26]. There is, however, a strong inter-observer variability in estimating the 
extent of these alterations, limiting its universal applicability [27]. This has led to the development 
of automated CT analysis in the field of pulmonary fibrosis. First, simple measures of lung density 
were used, but this later evolved to more complicated algorithms. CALIPER is such a well-validated 
software using pathological confirmed imaging data that it can accurately predict mortality [28]. 
This software was also able to define a new pattern, namely vessel related structures, which was 
a strong predictor of outcome [29]. In addition to delivering very important clinical information, 
ex vivo CT has also advanced our knowledge on the pathophysiology of pulmonary fibrosis, especially 
when combined with corresponding pCT (Figure 1c). Indeed, especially those areas containing no or 
limited fibrosis in CT scans are of particular interest, as these can provide some clues about the early 
pathophysiological mechanisms. Those areas without fibrosis on CT show small areas of increased 
attenuation on pCT, possibly reflecting fibroblast foci [30]. Interestingly, small airways were equally 
lost in samples characterized as minimally fibrotic or severely fibrotic on CT, indicating that small 
airway loss could also be an important process in restrictive lung disease [31]. The implementation of 
frozen pCT has advanced the field even more, as structural and morphological information derived 
from pCT could be combined with biological studies [32]. Using pCT to define areas of minimal, 
moderate and severe fibrosis, M cdonough et al. demonstrated that a core set of genes increasing 
or decreasing expression before fibrosis was histologically evident, and that this genetic signature 
continued to change with advanced fibrosis [33].
2.6. MRI of the Lung in Clinical Practice
The role of MRI in imaging of the heart and the great vessels is well established. For many years 
MRI was also a valuable "problem solving" technique in addition to CT for imaging the mediastinum, 
chest wall, diaphragm and lung. Nowadays however, and this is in a major part related to its technical 
improvement, CT is, together with chest X-ray, the major thoracic imaging modality to examine the chest 
including the areas thought previously to be the domain of problem-solving MRI. However, in patients 
who cannot receive intravascular iodine or in case radiation should be avoided, MRI of the chest may 
be considered as an alternative examination. Nevertheless, many research and development efforts 
have been made during recent years which have resulted in new and valuable applications that are 
very promising and that could once be implemented in clinical practice. There has been much interest 
in the role of MRI in the diagnosis of pulmonary embolism as a radiation-free alternative to CT [34]. 
In addition, imaging of pulmonary ventilation by MRI has become possible [35]. Diffusion-weighted 
magnetic resonance is another interesting application which has been used successfully to differentiate 
between malignant and benign lesions [36].
Diagnostics 2020,1 0 , 636 7 of 25
3. The Multimodal Toolbox for Biomedical Lung Disease Research
3.1. Correlating Non-Invasive In Vivo Imaging with Non-Destructive Ex Vivo Organ Imaging 
and Histopathology
Imaging modalities like pCT, MRI and optical imaging are indispensable and able to provide, 
in a non-invasive manner, a number of relevant morphological and functional measures to describe 
how different aspects of organs such as the lung change during health, disease and therapy in live 
animal models of lung disease [4,37]. In combination with one- and two-dimensional sampling 
methods, they result in an innovative technological pipeline based on combined imaging and lung 
function measurements that provide anatomical and functional biomarkers of lung disease and therapy 
dynamics in preclinical rodent models and whole-organ samples, up to detailed 2D examinations of 
isolated tissue.
We set out to illustrate the capabilities of different in vivo and ex vivo imaging modalities in animal 
models, in order to unravel different aspects of lung diseases, such as inflammatory processes versus 
tissue/airway remodeling. This will allow identification of onset and early changes in the inflammatory 
versus remodeling phase, enabling, for example, full evaluation of specific antifibrotic therapeutics.
3.2. Non-Invasive Modalities for Longitudinal In Vivo Lung Imaging
Importantly, introducing a longitudinal imaging approach in standard preclinical research practice 
reduces multifold the number of animals and animal suffering involved in longitudinal assessment of 
disease development and subsequent therapy testing, thereby improving the power of experiments, 
significantly reducing the large ethical burden associated with animal experimentation, and improving 
translatability of results. Moreover, the possibility to perform longitudinal studies, reducing variability 
in the analysis by quantitative parameters and increasing research throughput by automating image 
processing, are bound to provide long-term savings from the reductions in the number of animals 
and person-hours required for experimental work and analysis. Moreover, several imaging-derived 
biomarkers for lung disorders are fully translational and enable the setup of scientific collaborations 
and a service platform for the preclinical evaluation of innovative (antifibrotic) therapeutics.
3.2.1. In Vivo Longitudinal Lung pCT and pCT-Derived Biomarkers
pCT has an enormous yet unexploited potential for preclinical lung research. This potential has 
already been demonstrated for different lung diseases e.g., emphysema, fibrosis, infection, cancer 
and metastasis to longitudinally follow up disease processes [6,7,9,38- 40]. Similar to the clinical 
setting, pCT offers the capability to visually examine the entire lung for the presence of pathological 
alterations, evidenced by the appearance of radiodense areas that could indicate the presence of 
inflammatory infiltrates, lung consolidations, up to atelectatic or fibrotic areas in animal models of lung 
fibrosis compared to healthy control animals (Figure 2). Radiolucent areas detected on pCT indicate 
hyperinflation or emphysema in the lungs [6,41,42].
W here in the clinic diagnosis it is still most often a qualitative process based on observation 
by an experienced radiologist, preclinical research is in essence a quantitative investigation. Visual 
observations can be quantified based on a scoring system that reflects the extent of lung disease, 
enabling statistical evaluation of longitudinal changes in the observed lung disease burden [39,41,43].
Moreover, pCT enables the quantification of several morphological and anatomical lung biomarkers 
that describe disease progression and host response ideal for longitudinal follow-up of these diseases [8] . 
These biomarkers are extracted from a volume of interest covering the lungs thereby avoiding large 
blood vessels and the heart. Based on a full stacked histogram, a chosen threshold separates the voxels 
corresponding with radiodense areas from the radiolucent lung voxels, representing respectively the 
non-aerated lung volume and the aerated lung volume. Moreover, the total lung volume (sum of 
non-aerated and aerated lung volume, or all the voxels within the lungs) and mean densities within 
these lung volumes can be derived. Hereby, we can differentiate between pathologies presenting as
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hyperdense areas (malignancies, infection, infiltrations;, consolidation or atelectasis) versus pathologies 
causing radiolucence on CT such aa hyperi nfl ation, air trapping, or emphyse ma. The non-aeeaeed lung; 
volume is the biomarker that directly quantifies lung disease burden such as lung metastasis, infection, 
fibrosis and infSammation in animal models [8,38r39,42,4S- 47], and would be the direct correlate Co 
odher readouts to measure She severity of fibrotic disease such as hydroxyproline assay, or Ashcroft 
score from histological lung sections [8,9].
Figure 2. Overview of the uae of |j.CT and histology in a pre-clinical setting in a silica-induced lung 
fibrosh mouse modal. Mice were oropharyngeally instilled with crystallme silica particles (5 mg/mouse, 
bottom row) or saline (top row). Whole-body giCT scan ehowing the lungs of a mousr instilled with 
silica to induce fibrosis (A). Axial (B,G) and sagittal (C,H) views of non-fibrotk and fibrotic lungs.
Lung fibrosis ;s confirmed using histotogy at low magnification (12.5x—scale bar 2 mm) (D,/) and high 
magnification (5rx-scale bar 0.g mm—blue box) from areas indicated with yellow and rad cylinders in 
(C,H), showing normal and dense fibrotis regions consisting of silica clustering, vellular infiltration and 
granuloma formation (E,J). Polarization microscopy (scale bar 0.1 mml (F,K) allows visualization and 
quantification of the maturity of fibrotic lesions and silica clustering1.
By applying imaging-derived biomarkers for evaluating models of lung diseases, we were able 
to highlight previously overlooked aspects of lung diseases, thereby directly affecting our current 
knowledge and filling the gaps left by investigations that would only employ standard cross-sectional 
evaluation techniques. One of most important aspects that has previously been overlooked in lung 
disease research, is that mice often increase their total lung volume to compensate for the increased 
disease burden and loss in airspaces [8,9,38,44,48,49]. This should be considered as it influences the 
interpretation of other functional or imaging-derived read-outs, such as the mean lung density or 
lung volume changes. Where the non-aerated lung volume is a direct quantitative marker for the 
extent of pathology, the aerated lung volume is regarded as a biomarker of lung function. Indeed, it 
correlates with volumetric readouts from endpoint lung function measurements such as inspiratory 
capacity [8,9].
In the silica-induced fibrosis model (Figure 2 ), Dekoster et al. found, contrary to what would 
be expected for a restrictive disease, an enlarged aerated lung volume during the plateau of the 
fibrotic phase, consistent with the absence of a lowered inspiratory capacity, FVC, FEV01 or increased 
elasticity [9], lung function readouts that would typically be affected in human restrictive disease 
or in the bleomycin model [6,50]. The key to correct interpretation of lung function readouts lies in 
the consistently increased total lung volume retrieved from the pCT scans, reflecting enlargement 
of the lungs with silicosis. We interpret the enlargement of total lung volume, observed in this and 
other mouse models of lung diseases, as a compensation mechanism for the otherwise excessive 
loss of airspaces [8,49]. This phenomenon is absent in human patients, but in mouse models this 
enlargement of the lungs affects the interpretation of pCT- and lung function-derived readouts. Where
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lung function volumetric readouts may underestimate the presence of restrictive lung disease in 
this model, gCT offers unambiguous readouts on the presence of inflammation and fibrosis and a 
potential compensatory reaction thereto by enlargement of (aerated) lung volumes. These findings 
further emphasize the importance of adding gCT examinations to the standard preclinical workflow to 
characterize the response of mouse models to lung insults.
Next to extracting biomarkers of lung disease and host response thereto, gCT offers the additional 
capability/has an enormous potential for extracting functional biomarkers that reflect lung volumes 
and function in small animals. There are several options to extract functional biomarkers from lung 
gCT data. Certain dedicated gCT scanners allow the imaging of ventilated mice, controlled by 
directly connecting a scanner and a lung function measurement device and using a perturbation called 
"breath-hold". With this perturbation, a known volume of air is placed into the lungs for a short period 
of time (seconds), which allows the gCT to take several projections. To image the complete lungs, this 
perturbation needs to be repeated several times to result in a high-resolution lung scan. Apart from 
this perturbation, lung function measures may include forced oscillation lung function measurements 
that will result in specific tissue and airway related parameters, such as tissue elastance and airway 
resistance. This setup would allow direct comparison of lung physiology with parameters derived 
from imaging. On the other hand, we can use gCT as a method to derive functional lung biomarkers 
from free-breathing mice. Using respiratory gated protocols, gCT can deliver 4D data, meaning that 
several reconstructions cover different phases of the breathing cycle. This 4D gCT approach allows the 
extraction of additional biomarkers reflecting vital lung function, such as aerated lung volume and 
tidal volume, from free-breathing, live mice, thereby complementing data from state-of-the-art lung 
function measurements. These functional gCT-derived biomarkers can be derived in a longitudinal 
manner and can better reflect the physiological situation since no forced breathing or intubation is 
required compared to a ventilated approach. With gCT, it becomes possible to extract longitudinal 
data on certain aspects of lung function from the same animal without any risk of animal mortality.
The capabilities of gCT to provide longitudinal, quantifiable visual and biomarker data on different 
lung pathology aspects make gCT an efficient technology, ready for routine use in lung disease research. 
gCT can also complement the ample functional information that end-stage lung function measurements 
provide, while adding regional information on lung pathology, thereby establishing and increasing the 
synergism of both technologies for routine evaluation of lung conditions and their therapy.
3.2.2. Radiation Safety of Repeated Low-Dose gCT of Mouse Models of Lung Disease
In spite of the higher x-ray dose the animal is exposed to because of the higher resolution and 
sensitivity needed to provide a good quality mouse lung gCT-scan of an animal that is about 1000 
times smaller than a person, weekly repeated gCT remains without radiotoxic side effects to the lungs 
of healthy mice [7]. Nevertheless, any remaining concerns related to potential radiotoxicity of the 
cumulative radiation dose to diseased animals need to be ruled out before we can safely implement 
gCT for longitudinal studies. The ionizing radiation in gCT acts on biological tissue through two 
main effects: 1/ the x-rays interact with water molecules resulting in reactive oxygen species and free 
radicals and 2/ x-rays disrupt the chemical bonds of several biomolecules (nucleic acids, proteins, 
lipids etc.) [51,52] For example, when x-rays interact with genetic material, they create DNA base 
modifications, base damage or double-stranded DNA breaks. To assess the biological effects of 
radiation, not only the cumulative dose of radiation is important, but also the factors that determine 
this, such as dose-rate, scan frequency and type of exposed tissue. Depending on the intrinsic repair 
capacity, tissues exposed to the relatively low radiation dose of gCT are able to repair the damage.
A remaining hurdle towards routinely implementing longitudinal gCT for lung research would 
be that due to hardware restrictions, it cannot be excluded that the relatively high x-ray exposure 
administered during the current available high-resolution gCT protocol may still have an effect on the 
specific aspects of the disease model, such as a possibly altered immune response or alterations in the 
tissue remodeling processes that are specific to the pathogenesis of lung fibrosis. The assurance of low,
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harmless dose exposure is extremely relevant in lung disease models that involve rapidly dividing cells, 
such as the metastatic, tissue remodeling and inflammatory processes investigated in lung research.
An important step thereto has been taken by investigating the potential effects of repeated x-ray 
exposure during gCT scanning of animal models of lung metastasis and fibrosis (as models involving 
rapidly dividing cells may be particularly sensitive to radiation), including potentially altered relevant 
readouts such as immune cell proliferation and apoptosis. Berghen et al. found a disease-independent 
small but consistent decrease in circulating platelet and lymphocytes after a weekly repeated 4D 
respiratory-gated scan for five weeks [53]. Based on these observations, they established an upper safety 
limit of 540-699 mGy/scan to be delivered on a weekly basis five times with repeated gCT. This limit 
can be seen as physiologically safe but with a sub-clinical drop in certain blood cell counts. These effects 
can be completely eliminated by using less-demanding qCT protocols, such as by optimizing 3D 
imaging protocols and reducing the dose delivered to the mice with each scan [53] . Importantly, the 
conclusion is that gCT protocols can be designed that do not interfere with radiosensitive processes 
in the body. Radiation safety is a necessary step for the introduction of qCT into routine preclinical 
practice, enabling lung researchers to benefit from all its advantages without concerns for radiotoxicity, 
to benefit the direct translation of imaging examination results from mouse to patients and back.
3.2.3. Dose Reduction Approaches for Respiratory-Gated gCT
In recent years, a variety of methods have been proposed to decrease the radiation dose 
administered in preclinical in vivo lung examinations. These methods comprise improvements in 
system hardware and image reconstruction algorithms alike. In early experiments, time-resolved 
volumes were reconstructed using filtered back projection (FBP); i.e., x-ray projections were 
continuously acquired alongside a corresponding respiratory signal and respiratory-gated volumes 
were retrospectively obtained by reconstructing only those projections measured in a desired motion 
state (respiration phase). To reconstruct the entire respiratory cycle, i.e., to obtain 4D data consisting 
of 3D volumes at different time points, several reconstructions have to be performed, preferably 
with overlapping phases. Since only a fraction of all acquired data is used for the reconstruction 
of a single volume, image quality is usually degraded by streak artifacts unless vast amounts of 
projections are available, eventually increasing radiation dose [54- 57]. Ultra-high-resolution in vivo 
acquisitions of the lung might also require additional cardiac-gating since uncompensated cardiac 
motion impairs image quality and reduces spatial resolution due to motion artifacts. In turn, even 
more projections are required to maintain a sufficient image quality in case of simultaneous cardiac- 
and respiratory-gating, adding to the administered radiation dose. If only a single respiratory motion 
state is desired, prospective gating might be used; i.e., projections are only acquired if the lung is in a 
particular motion state. This, however, requires dedicated hardware that is either difficult to handle 
or might not be readily available in practice, e.g., ventilators with a feedback-loop to the micro-CT 
scanner or pulsed x-ray sources [58,59]. Dedicated iterative reconstruction methods have proven 
to reduce the administered radiation dose by an order of magnitude while maintaining the image 
quality and accuracy of derived quantitative measures [60- 62]. In brief, these methods incorporate 
prior knowledge into the image reconstruction process identifying and removing noise and artifacts. 
For example, one might assume that the CT-values of the specimen under investigation are piecewise 
constant or that adjacent breathing phases show similar anatomical structures. An even higher 
radiation dose reduction is promised by motion compensation (MoCo) methods that have initially 
been developed for image-guided radiation therapy and have been translated to clinical PET, clinical 
MRI and preclinical imaging later on [63- 67]. In particular, given a series of respiratory-gated FBP 
reconstructions covering the complete respiratory cycle, these methods estimate motion vector fields 
between adjacent respiratory phases and ensure that these vector fields are cyclic. As soon as all 
motion vector fields are available, the initial reconstructions are deformed and superimposed to 
match a desired respiratory phase. Since all acquired data contribute to each final image, this process 
is much more dose-efficient compared to previous algorithms (Figure 3, Video S1a and S1b in the
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Supplementary Materials). However, one should note that the computational demands for iterative 
reconstructions or MoCo methods are higher compared to conventional FBP reconstructions. While an 
FBP reconstruction can be performed within seconds using modern hardware, algorithms that are 
more sophisticated might exhibit runtimes in the order of minutes or hours. Hence, conventional 
respiratory-gated FBP reconstructions are available in almost all commercial micro-CT systems while 
other methods, though promising, are only adopted slowly into preclinical practice.
(A) (B)
Standard Reconstruction Motion Compensation
(C ) (D )
Figure 3. Motion correction of in vivo iCT to improve image quality and dose exposure. 
Respi ratory-galed 4D pCT rescon struct ions of a mouse with a respiratory windo w width o f 20%.
The top row shows reconstructions obtained with the full doses of the used reference protocol (A,B) 
and the bottom row show s reconstructions obtained using only 20%> of tire reference dose (C, D). "The 
standard reconstruction (FBP) results in severe artifacts if dose is reduced while a motion compensation 
(MoCo) approach results in an image quality sufficient for most qualitative and quantitative tasks (D).
(C = 50 HU, W = 400 HU). Videos are available as a supplementary: Video S1a and S1b.
3.2.4. In Vivo MRI for Small Animal Lung Fibrosis Imaging
The rationale for developing M RI as a complementary imaging option is because pCT lacks 
the sensitivity to distinguish inflammatory from tissue remodeling piocesses, a concept that is very 
relevant for the pathogenesis of lung; diseases, particularly in lung fibrosis. M RI is a more versatile 
tonl that io theory could enable monitoring of different cellular parameters and contrest mechanisms, 
providing complementary information to pCT on different pathogenic processes in the lung, ultimately 
aiming at discriminating between inflammatory and lung remodeling processes in vivo. A model of 
particular interest in the exploration of the potential of MRI to distinguish between inflammation and 
fibrosis is (bleomycin-induced) lung fibrosis, as this disease involves both very well characterized 
initial inflammation and prognessive fibrosis. M RI developments, in line with previous work [5], 
are directed tpwards designing advanced lung MRI and data processing methods that 'will enable
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to unravel inflammation from lung fibrosis and to detect early onset, followed by mild pathology, 
ultimately aiming at improving the understanding and treatment of pulmonary fibrosis in relevant 
animal models and towards translation in patients. This is relevant for screening treatment options 
that can truly halt or even reverse lung fibrosis.
However, MRI of the lungs is not obvious. Lungs are mainly filled with air, which results in a 
very low inherent signal that is available for lung imaging. Moreover, the many tissue-air interfaces 
result in magnetic susceptibility effects that may cause imaging artifacts and accelerate signal decay 
(short T2/T2*). Therefore, conventional MRI protocols result in little or no signal so that lung tissue 
appears dark on MR images. Nonetheless, the zero signal in the lungs can provide a useful background 
against which to recognize abnormalities that produce an increase in signal, such as lung fibrosis or 
cellular infiltration [68- 72]. Nevertheless, the susceptibility effects at tissue-air interfaces are likely 
to hinder the early detection of smaller fibrotic patches or sites of disease onset at earlier stages of 
pathogenesis when using conventional MRI protocols. To overcome these limitations, we can use a 
pulse sequence allowing for ultra-short echo times (UTE) [73]. In UTE MRI, image contrast is less 
influenced by air-tissue susceptibility effects, and the detection of tissues that particularly suffer from 
these effects, such as lung and fibrotic tissue, therefore improves significantly compared to conventional 
pulse sequences [5]. UTE MRI is currently under evaluation for clinical applications [74,75], but was 
only recently introduced for mouse lung imaging [76- 78]. We have shown that its potential in 
evaluating lung fibrosis development is promising [5], but its ability to discriminate inflammatory 
from tissue-remodeling processes remains under-evaluated.
UTE-MRI can potentially monitor inflammatory events using established approaches that utilize 
iron oxide-based nanoparticles [79,80]. Alternatively, 19F-MRI can be used to visualize the accumulation 
of immune cells in the lungs with disease progression. In contrast to conventional proton-based MRI, 
19F-MRI can visualize cells labeled with 19F-based contrast agents without a misleading background. 
Hereby, the visualization of immune cells after systemic administration of 19F-based agents has 
already been established [81,82]. Detection of lung pathology may suffer from movement artifacts 
caused by breathing and the beating heart, unless the acquisition is triggered to this motion. Motion 
can be monitored based on the MRI signal intensity variations induced by cardiac and respiratory 
movements [83], a technique known as "self-gated" MRI. This technique obviates the need for 
respiration pads and ECG leads, thereby enhancing the throughput in animal studies. The self-gated 
MRI technique has been introduced for mouse cardiac and rat liver imaging [84- 86], and for (mouse) 
lung MRI [5].
MRI developments that will enable us to identify the switch from inflammatory to lung fibrosis 
will greatly improve our understanding and treatment of pulmonary fibrosis and is fully translational. 
Although further development is needed before MRI can be implemented as such, this is relevant for 
screening treatment options that can truly halt or even reverse lung fibrosis as these would improve 
the merely symptomatic or anti-inflammatory treatment options that are currently available [2].
3.2.5. In Vivo Optical Imaging of Lung Diseases: From the Whole-Body Level to the Cellular Scale
Whereas pCT enables the visualization of inflammation and fibrosis onset and progression on the 
level of the whole lung, optical imaging approaches are currently underused, but hold the promising 
potential to provide complementary information on the presence of certain biomarkers of disease at a 
whole-body, whole-organ and/or microscopic level.
On the whole-body level, bioluminescence or fluorescence imaging of cell populations labeled with 
genetically expressed reporter genes is available to track pathogens during lung infection, metastasis 
or inflammatory processes in small rodents [4,38,45,87,88]. With specific fluorescent dyes, tagging a 
certain cell, protein or responsive to a certain enzymatic marker relevant to the disease process, certain 
contributions from the immune response to fibrosing disease development can be non-invasively 
monitored with optical imaging [89]. W hen using dyes, these probes have translational potential 
for application to human samples such as the BAL fluid. Similar to radionuclide-based imaging
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approaches such as PET or SPECT, the success of any probe or tracer-based approach to be a diagnostic 
or prognostic biomarker depends on several factors such as biodistribution, but most importantly on 
the specificity of a certain tracer for a particular cell or protein and thorough validation of its role in the 
disease process [37] .
It currently remains a challenge to observe in real time and repeatedly the dynamics of cellular 
interactions in the lung at a sufficiently high resolution. Intravital microscopy (IVM) approaches enable 
the observation of cellular processes in the lung in real time at microscopic resolution, which may 
lead to novel observations and insights in the dynamics of pathogenic processes and interactions 
with the host. This requires direct access to the lungs. One way to achieve this is by introducing 
an optical window in the chest wall to contact the lung. This has been technically achieved and 
allowed real-time investigation of lung microvasculature or inflammation in the context of metastasis 
or ILD with single-cell resolution up to several hours, but remains a terminal procedure due to its 
invasiveness [90- 95].
Another option to access the lung is the use of IVM by fibered confocal fluorescence microscopy 
(FCFM) via an endoscopic procedure as an innovative, complementary optical imaging technique 
to visualize processes in the lung in real time and at microscopic resolution [96]. By rational use 
of activatable and/or environment-sensitive fluorescent probes specific to a certain cell or molecule, 
real-time fluorescence microscopy inside the lungs of a free-breathing, anesthetized mouse comes within 
reach [91,97- 102]; e.g., probes for targeted imaging of subpopulations of macrophages, and probes to 
image cathepsin activity, which may be relevant in cystic fibrosis and fibrosing lung disease. Thereby, 
we will be able to visualize specific processes such as the extent of inflammation in vivo at different 
time points in the same animal, in interaction with other processes based on labeling with green 
and red fluorescent probes/dyes. IVM technology by FCFM can be regarded as an addition to the 
available imaging technology platform for the preclinical evaluation of specific contrast agents targeting 
molecular and/ or cellular biomarkers of certain stages of disease. This has a direct potential for 
clinical translation for improved differential diagnosis, in the clinical context better known by its name 
"probe-based confocal laser endomicroscopy" (pCLE) [103].
3.3. Non-Destructive 3D Ex Vivo Lung Imaging
As an alternative for the current 2D ex vivo validation options, 3D examination of the intact 
organ would result in a better quantifiable and comprehensive analysis method, specifically relevant 
to lung research because of the need to evaluate the lungs as a whole in 3D. Sample selection for 
ex vivo examination can be done at relevant time points during pathogenesis as defined by in vivo 
imaging. Thereby, a technological gap is bridged by providing the missing link between whole-body 
imaging methods that visualize overall anatomy and disease in 3D, and microscopic techniques that 
give information with high, cellular resolution in 2D or with limited penetration depth and with a 
very small field-of-view, such as the aforementioned IVM approaches. Such technology enables us to 
complement in vivo findings with a more detailed analysis in the context of the intact organ.
3.3.1. Ex Vivo gCT Visualizes Lung Parenchyma and Vasculature in 3D
Ex vivo gCT is a significant step in correlating in vivo gCT and ex vivo histological examination 
of diseased lung tissue for comprehensive preclinical research. It is one of few methods providing 
3D imaging of the whole extracted organ with isotropic micrometer resolution (Figure 4, Video S2 in 
the Supplementary Materials). Moreover, this modality, combined with contrast agent perfusion or 
staining methods, produces images that can compete with classical histological sections [104- 106]. 
gCT allows fast automated analysis of hundreds of cross-sectional images separated by a few microns. 
Any attempt to reach equivalent results using histological methods would be a tedious, time consuming, 
and most importantly, a sample-destructive process.
gCT-captured datasets enable advanced 3D analysis, modeling and internal structure assessment 
of the organ as well as interrelations between its subcomponents. Specified perfusion and/or staining
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provides images of chosen tissues, for instance, vascular networks (Figure 4C, Video S2 in the 
Supplementary Materials). High resolution ex vivo pCT methods enable qualitative and quantitative 
characterization of the vascular network of the lungs and analysis of morphometric parameters like 
volume, surface, and local diameter of the vessels [107], along with evaluation of complexity of the 
lung circulation system using, for instance, connectivity density or fractal dimension.
Lung vasculature Lung parenchyma Parenchymal -  vascular
overlay
Figure 4. High resolution ex vivo pCT of isolated rodent lung;. (A) Reconstructed pCT of whole mouse 
lung, visualizing spatial diffetences in lung pa thology; (B) enlargement of the yellow box in A, zooming 
in on spatial differences in areas with localized lung inflammation (red circte) and non-pathologiccl 
regions (green circle ); (C-E) lax: vivo |iCT o f ra t lung with bar ium-based vasc ular perfusion. Vascular 
nelwork rendered with maximum intensity projection (MIP) (C); lung parenchyma visualized using 
minimum intensity projection (MinIP) (D); an overlay of parenchymal and vascular tissue (E). Scale bar 
5 mm. Video is available as Supplementary Video S2.
Lung vasculature high resolution ex vivo pCT imaging is invaluable in research on pathophysiology 
of numerous lung illnesses that often reduce patients' quality of life by causing shortness of breath and 
chest pain. Grou p o f dieorders known ac pulm onary vatcular dise ase (PVD) such as pu l monary arterial 
hypertension or pulmonary embolism, significantly affect blood flow in the pulmonary circulation 
system leeulting in severe disability or death [108], waeranting towards the important vascular 
component in lung1 disocders. High reso(ution ex viv o irCT can vfeuaflze patho logical angiogenesis, 
present in chr onic thromboembolism1 asthma, cystic fibrosis an d especially in primary tumors [109,110].
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The qCT results are not direct. During the measurement, the detector records hundreds of 2D 
projections, which are then subjected to an image reconstruction process, as a result of which we obtain 
cross-sectional images of the scanned object. Optimization of image reconstruction parameters, as well 
as the modification of transfer functions when viewing the 3D model, provide an opportunity to zoom 
in and observe extremely small and different details based on the same scan.
3.3.2. Optical Imaging of Intact Lungs with OPT and SPIM
Next to ex vivo qCT, optical projection tomography (OPT) [111] and selective plane illumination 
microscopy (SPIM) [112] of optically cleared mouse lungs can be a non-destructive alternative for the 
ex vivo validation options that involve mainly histological sampling of mouse lungs in 2D. OPT can 
be thought of as an implementation of the principles of CT, but in the visible region of the spectrum. 
SPIM is a technique in which optical sectioning is achieved directly, by exciting fluorescence with 
a thin sheet of laser light. OPT and SPIM are novel meso- and microscopic approaches that enable 
us to validate and complement in vivo imaging results and to study the spatial distribution of lung 
pathology in intact mouse lungs in 3D with cellular resolution [111,113]. As OPT and SPIM are optical 
imaging modalities, we have the possibility to exploit different fluorescence channels, thereby opening 
the door towards multiplexing of different signals from differentially labelled cells.
Given the size and optical properties of adult mouse lungs, imaging them in toto in their native state 
is not practical. To avoid the tedious and destructive process of physically sectioning the lungs, several 
methods have been proposed to chemically clear tissues and organs to make them optically transparent. 
These include organic solvent-based techniques such as treatment with benzyl alcohol + benzyl benzoate 
(BABB) [111] or ethyl cinnamate [114], aqueous methods such as the CUBIC family of protocols [115], 
or hydrogel-based protocols such as CLARITY [116] or expansion microscopy [117]. Each method has 
its advantages and disadvantages in terms of clearing quality, fluorescence preservation, toxicity of 
reagents, and time required; see Ueda et al. [118] for a recent review.
The combination of OPT and/or SPIM with chemical clearing of intact murine lungs is an important 
addition to the technological toolbox for the study of lung diseases. Although it is an ex vivo technique, 
and therefore limited to end-point analyses, it can add significant value. The enormous variety of 
molecularly specific labels (fluorescent proteins, fluorophore-labelled antibodies, small molecular dyes) 
available for optical imaging mean that the 3D distribution of specific cell types or cells in particular 
states can be visualized. The fact that the entire, intact lung can be imaged permits the detection of 
rare cells or events that would likely be missed if only sub-regions of the lung are examined.
Other than simply providing "additional data", the datasets generated by OPT and SPIM of ex 
vivo, cleared lungs have two main uses. Firstly, they can be correlated with previous in vivo data, 
to confirm observations and re-examine regions using new contrasts. Secondly, they can be used to 
guide future physical sectioning for traditional 2D histology of lung slices, if required. This is possible 
because at least some of the clearing protocols (e.g., treatment with BABB) are reversible; that is, a lung 
can be chemically cleared, imaged in 3D, and then returned to its initial state by inverting the clearing 
protocol [119].
We have been able to successfully demonstrate the possibility to optically clear large samples 
such as adult mouse lungs for compatibility with OPT and SPIM [120] (Figure 5, Video S3a and S3b in 
the Supplementary Materials). For this we generally use the BABB protocol, for its simplicity, speed, 
and quality of clearing. Figure 5 shows a cleared mouse lung imaged using both OPT (A-D) and SPIM 
(E-H ), demonstrating its power for non-destructive optical sectioning of inflamed and fibrotic lungs 
based on autofluorescence of tissue components. The OPT and SPIM-approach benefit the experimental 
workflow to provide regional information on lung pathology that can be used for identification of 
areas of interest for subsequent classical histology on the same lung samples for direct correlation.
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Transmission Fluorescence
Figure 5. Optical Prejection Tomography (OPT) and Selective Plane Illumination Microscopy (SPIM) 
of silica-induced lung fibrosis. Mice were oropharyngeally instilled with crystalline silica particles 
(5 mg/mice) , sacrificed and imaged 35 days after instillation. OPT transmission imaging of o ptically 
cleared lungs shown a s a "raw" p rejection (A) and a s a reconstructed slice ( B). The regions with 
concentrationa of silica particles can be seen as grey blotches in the transmission images (A,B).
OPT fluoeescent images of projected (C) and reconstructed (D) lungs. In fluorescence, the larger 
vascular structures can lee seen in the Cy5 channel (red in images C,D)s and tine geneeal structure 
is visualized using autofluorescence in the GFP channel (cyan in C,D). A more in-depth and spatial 
analysts of optisally clea zed lungs using SPtM shows a transmis sion image IE) and corresponding 
flusrescence optical s lices in the Cy5 (F) and GFP (G) channels. (E) is a transmission ima ge taken in 
the SPIM showing a field of view with regions containing silica particles (note that this is a traditional 
wide-field image, not an optical sectionl. Optical sections of fluorescence are shown in (F-H), whefe 
regions with both normal structure and fibrosis can be seen. Tire images in (F,G) are shown in color 
overlay in (H). 3D visualizations of the OPT canbe found as Supplementary Vidros S3a and S3b.
4. Discussion
4.1. A Multimodal Lung Imaging Approach to Improve Translation between Bench and Bedside
Despite the high burden of disease, effective anti-fibrotic treatments for many (idiopatic) lung 
fibrosis patients are not yet available. This is surprising, as many pathways have e een successful^ 
challenged in preclinical models. with exponential growth in studies and compounds but limiizd 
translation towards the clinic. Some of these failures might be attributed to the relativzly poor 
perfermance of the prechmcal models and in particular the use of end-stage analyses that likely 
refleci the sum of (disease activity oves time more than the extent of the disease process iiself. Most 
of the preclinical models are self-limiting, .hereby po(entially overestimating the effect size of any 
intervention. The highs cosis associated wiih the modal set-ups and the laborious pathology analysis 
also leads to a relative lack o. replicated experiments.
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The availability of novel diagnostic technologies now challenges the current gold standard and 
seriously questions the methodological dogmas in preclinical lung research, and suggests that these 
issues can be overcome by the development of imaging methods that catch the dynamics of the model 
and therefore can assess disease activity and outcome over time, and that can potentially replace the 
need for full pathology analysis in screening and replication set-ups. Because of the disappointing 
results in translating mouse model results to the clinic [1,2], many questions remain in particular 
related to the choice of the optimal biomarker(s) to address a specific research question, evaluate mouse 
models for their validity and experimental therapies for translational studies.
Biomarkers that can be derived from in vivo imaging have proved to be relevant for the in vivo 
evaluation of lung fibrosis and its therapy, and the host response thereto [8,49]. Based on the finding 
that mouse lungs expand significantly during lung fibrosis progression— a phenomenon that remains 
largely overlooked— it proves to be essential that lung fibrosis and its therapy are evaluated in 3D 
and over the entire lung [8,9,49]. This is in contrast to the current preclinical gold standard of 2D 
histological sampling methods, which overlook potential compensatory mechanisms in the mouse 
lung and therefore may underestimate the true extent of pathology. Adding pCT-derived biomarkers 
throughout lung disease and therapy investigations should become part of the new standard diagnostic 
methods in experimental lung disease investigations. Better evaluation of therapy results in available 
and novel rodent models of lung disease will be essential in resolving the issues with translation of 
results from bench to bedside. The example from the chronic lung fibrosis model showcased here 
indicates that direct translation from the clinical view on obstructive and restrictive diseases is not 
so straightforward in these animal models and more importantly, it demonstrates that in vivo pCT 
is essential for the correct interpretation of preclinical lung research [9]. We expect a non-invasive 
imaging approach to enable us to identify and resolve at least some of the anomalies encountered 
when translating apparent successful preclinical therapy trials to patients.
To have a strong contribution to the mechanistic knowledge about pulmonary diseases 
and co-morbidities and towards improving disease management, we need complementary and 
comprehensive approaches. By innovating diagnostic technologies as outlined, we can push the 
state-of-the-art forward and break new ground. Improving and applying imaging technologies may 
lead to novel observations and new insights. A combination of multiple state-of-the-art and innovative 
in vivo and ex vivo imaging modalities and techniques such as (p)CT, lung MRI and MoCo, intravital 
microscopy, high-resolution ex vivo pCT, OPT and SPIM can ultimately overcome limitations of the 
individual techniques and provide complementary information.
4.2. Ethical Impact and Considerations ofNon-Invasive Imaging in Lung Research
Given the type of research, there is no alternative to the use of animals for studying the complex 
interplay of host immune cells and triggers of pathology in the different processes that are characteristic 
of pulmonary diseases. Nowadays a hot topic, and an always important societal challenge that the lung 
research community faces, is how we deal with the ethical burden related to research involving live 
animals. The acceptability of using animals in research rests on the twin expectations that the research 
findings will be meaningful and substantial, and that the suffering will be minimal. For scientific 
justification, the validity of science is dependent on the validity of the animal model; that is, dependent 
upon the extent to which experimental findings in the animal model can be generalized to other species, 
particularly humans. The ethical justification is based upon the view that increasing the knowledge 
base makes it possible to develop therapies that mitigate pain and suffering caused by illness and 
trauma, and thereby responds to the moral imperative to do well. It assumes that research can be 
carried out with no or minimal discomfort or distress to the animal research subjects, and that any pain 
and suffering experience is compensated for by the alleviation of human pain and suffering caused by 
disease and injury. The focused procedures and efforts of a non-invasive imaging approach answer 
to both the scientific and ethical justification. Such an approach will directly lead to a reduction and 
refinement in the use of animal models in biomedical research because of the strong focus on the
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development, optimization and use of non-invasive imaging methods and will diminish significantly 
the "harm -to-benefit" ratio in the justification of animal use in this area of research. Innovation in 
imaging will immediately be able to suggest generic non-invasive imaging protocols for the broad 
lung research field, yielding a more accurate evaluation of animal models relevant to human disease. 
Imaging allows us to longitudinally monitor individual animals, thereby extracting meaningful 
biomarkers before the onset of signs of distress, greatly reducing the number of animals that are 
typically used in these kinds of studies.
Most, if not all, of the multi-modal imaging approaches showcased here are generic and will 
have important impacts on the assessment of lung diseases in general (e.g., infection models and lung 
tumor/metastasis models, cystic fibrosis models, COPD and asthma models, and other (transgenic) 
lung fibrosis models).
5. Conclusions
Whereas clinical practice is unthinkable without imaging for disease evaluation, in the preclinical 
field the available imaging technology is still most often not employed in spite of its obvious advantages. 
More interdisciplinary collaboration as described in this showcase may change this and may bring 
clinicians, lung and imaging research communities closer together, to interact and integrate more for 
the benefit of the research community, the animals used in the studies, and patients. We strongly 
believe that a multifaceted approach to lung disorders, including cooperation between those doing 
basic research and clinical studies, will improve translation, our understanding of the disease and, 
above all, provide benefits for our patients. Our imaging approach will therefore not only impact on 
academic research, but also on business development through industry collaborations extending into 
pharma companies that may change their study design regarding drug testing towards implementation 
of a more imaging-based approach.
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